New­ly de­buted biotech shoots for $40M IPO; In­tel­lia touts new an­i­mal da­ta on CRISPR/Cas9

⇨ Just 8 months af­ter mak­ing its de­but at the be­gin­ning of the year, Cam­bridge, MA-based Cue Bio­phar­ma has filed for a $40 mil­lion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.